Last reviewed · How we verify
MV-CHIK high dose — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
MV-CHIK high dose (MV-CHIK high dose) — Themis Bioscience GmbH.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| MV-CHIK high dose TARGET | MV-CHIK high dose | Themis Bioscience GmbH | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- MV-CHIK high dose CI watch — RSS
- MV-CHIK high dose CI watch — Atom
- MV-CHIK high dose CI watch — JSON
- MV-CHIK high dose alone — RSS
Cite this brief
Drug Landscape (2026). MV-CHIK high dose — Competitive Intelligence Brief. https://druglandscape.com/ci/mv-chik-high-dose. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab